Items Tagged ‘Taxol’

September 29th, 2015

No Benefit with Addition of Onartuzumab to Taxol® with or without Avastin® in Triple-Negative Breast Cancer

By

The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are […]

View full entry

Tags: avastin, Breast Cancer, metastatic, Metastatic Breast Cancer, Onatuzumab, Taxol, triple negative


April 30th, 2015

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer

By

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved disease-free survival. These findings were released online by the journal The Lancet. Node-positive breast cancer means that cancer cells from the breast have been found in the lymph nodes under the arm. Although […]

View full entry

Tags: Breast Cancer, cyclophosphamide, Cytoxan, early-stage, Ellence, epirubicin, fluorouracil, News, node-positive, paclitaxel, Stages II-III Breast Cancer, Taxol


April 29th, 2015

Combination of Avastin®, Taxol®, and Carboplatin Improves Survival in Recurrent Platinum-Sensitive Ovarian Cancer

By

The addition of Avastin® (bevacizumab) to Taxol® (paclitaxel) and carboplatin for the treatment of recurrent platinum-sensitive ovarian cancer appears to improve survival. These findings were presented at the 2015 Annual Meeting on Women’s Cancer, March 28–31, in Chicago, Illinois. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more […]

View full entry

Tags: avastin, bevacizumab, carboplatin, clinical trial, News, Ovarian Cancer, paclitaxel, platinum sensitive, Taxol


March 30th, 2015

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer

By

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the […]

View full entry

Tags: Bladder Cancer, News, paclitaxel, pazopanib, Phase II study, Recurrent Bladder Cancer, Stages II-III Bladder Cancer, Taxol, Votrient